Viropro Financials
Based on the analysis of Viropro's profitability, liquidity, and operating efficiency, Viropro is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Viropro's Property Plant Equipment is very stable compared to the past year. Key indicators impacting Viropro's financial strength include:
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.11 | 0.1205 |
|
| |||||
| Current Ratio | 0.29 | 0.3 |
|
|
The essential information of the day-to-day investment outlook for Viropro includes many different criteria found on its balance sheet. An individual investor should monitor Viropro's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Viropro.
Net Income |
|
Viropro | Select Account or Indicator | Build AI portfolio with Viropro Stock |
Viropro Stock Summary
Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. VIROPRO INC operates under Biotechnology classification in the United States and is traded on PNK Exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US9282422057 |
| Business Address | 2151 OToole Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.viropro.net |
| Phone | 650 300 5190 |
| Currency | USD - US Dollar |
Viropro Key Financial Ratios
| Operating Margin | (2.09) % | ||||
| Price To Sales | 18.15 X | ||||
| Revenue | 571.1 K | ||||
| Net Income | (1.01 M) | ||||
| Debt To Equity | 0.57 % |
Viropro Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Viropro's current stock value. Our valuation model uses many indicators to compare Viropro value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viropro competition to find correlations between indicators driving Viropro's intrinsic value. More Info.Viropro is rated fifth in operating margin category among its peers. It is rated first in current valuation category among its peers . At this time, Viropro's Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viropro's earnings, one of the primary drivers of an investment's value.Viropro Systematic Risk
Viropro's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Viropro volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on Viropro correlated with the market. If Beta is less than 0 Viropro generally moves in the opposite direction as compared to the market. If Viropro Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Viropro is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Viropro is generally in the same direction as the market. If Beta > 1 Viropro moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Viropro Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Viropro's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Viropro growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viropro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viropro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth 1.19 |
The market value of Viropro is measured differently than its book value, which is the value of Viropro that is recorded on the company's balance sheet. Investors also form their own opinion of Viropro's value that differs from its market value or its book value, called intrinsic value, which is Viropro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viropro's market value can be influenced by many factors that don't directly affect Viropro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viropro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.